SpringWorks Therapeutics, Inc.Stamford, Connecticut, United States
Disclosure information not submitted.
Paper 102 - EFFICACY OF NIROGACESTAT IN PATIENTS WITH DESMOID TUMORS AND POOR PROGNOSTIC FACTORS: PATIENT-REPORTED OUTCOMES, PROGRESSION-FREE SURVIVAL, AND OBJECTIVE RESPONSE RATE IN THE PHASE 3 DEFI TRIAL
Saturday, November 16, 20243:30 PM – 4:30 PM PST
Paper 103 - NIROGACESTAT TREATMENT IN ADULT PATIENTS WITH DESMOID TUMORS: LONG-TERM EFFICACY AND SAFETY FROM THE PHASE 3 DEFI TRIAL
